Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells

NCT02045745 ↗

Phase 1/2 Unknown 10 enrolled Red de Terapia Celular Castilla y León Hematology and hemotherapy Foundation · collab Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán · collab Spanish National Health System · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to analyze the safety and feasibility of the implantation of autologous mesenchymal stem cells (MSCs) expanded "in vitro" and administered directly in the lung line of suture as a treatment for patients at risk of postoperative air leaks after lung resection.

Timeline

Start: 2013-12
Primary completion: 2017-12
Completion: 2017-12

Publications

Jimenez MF, Gomez-Hernandez MT, Villaron EM, Lopez-Parra M, Sanchez-Guijo F. Autologous mesenchymal stromal cells embedded with Tissucol Duo(R) for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up. Stem Cell Res Ther. 2023 Oct 31;14(1):313. doi: 10.1186/s13287-023-03545-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	mesenchymal stem cells	Cell therapy	—	Other

Indications

No indication recorded.